Lanreotide Completed Phase 4 Trials for Congenital Hyperinsulinism (CHI) Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01070758Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy